Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.
The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.
Key findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.